Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (ACTION-1)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05477576 |
|
Recruitment Status :
Active, not recruiting
First Posted : July 28, 2022
Last Update Posted : April 29, 2024
|
Sponsor:
RayzeBio, Inc.
Information provided by (Responsible Party):
RayzeBio, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2 in subjects with inoperable, advanced, well-differentiated, somatostatin receptor expressing (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following treatment with Lutetium 177-labelled somatostatin analogue (177Lu-SSA) therapy, such as 177Lu-DOTATATE or 177Lu-DOTATOC (177Lu-DOTATATE/TOC), or 177Lu-high affinity [HA]-DOTATATE.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| GEP-NET Gastroenteropancreatic Neuroendocrine Tumor Gastroenteropancreatic Neuroendocrine Tumor Disease Neuroendocrine Tumors Carcinoid Carcinoid Tumor Pancreatic NET | Drug: RYZ101 Drug: Everolimus 10 mg Drug: Sunitinib 37.5 MG Drug: Octreotide LAR 60 MG Injection Drug: Lanreotide 120Mg Sa Susp Inj Syringe | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 288 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2 in subjects with inoperable, advanced, well-differentiated, somatostatin receptor expressing (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following treatment with Lutetium 177-labelled somatostatin analogue (177Lu-SSA) therapy, such as 177Lu-DOTATATE or 177Lu-DOTATOC (177Lu-DOTATATE/TOC), or 177Lu-high affinity [HA]-DOTATATE. |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy |
| Actual Study Start Date : | March 24, 2022 |
| Estimated Primary Completion Date : | July 2025 |
| Estimated Study Completion Date : | July 2028 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Phase 1b - RYZ101
Part 1 is an uncontrolled dose de-escalation study to confirm the safety and determine the RP3D of RYZ101 based on Bayesian optimal interval design. Eligible participants will be enrolled in cohorts of 6 to receive RYZ101 up to 4 infusions every 8 weeks. If the initial dose level is not tolerated, the dose will be de-escalated; up to 3 dose levels will be assessed.
|
Drug: RYZ101
RP3D as determined in Phase 1b |
|
Active Comparator: Phase 3 - RYZ101
Actinium 225 radiolabeled somatostatin analog (SSA) for injection
|
Drug: RYZ101
RP3D as determined in Phase 1b |
|
Active Comparator: Phase 3 - Standard of Care
Investigator's choice of standard of care between everolimus, sunitinib, octreotide, or lanreotide.
|
Drug: Everolimus 10 mg
Everolimus 10 mg daily by mouth Drug: Sunitinib 37.5 MG Sunitinib 37.5 mg daily by mouth Drug: Octreotide LAR 60 MG Injection High-dose octreotide LAR 60 mg Q4W by i.m. injection Drug: Lanreotide 120Mg Sa Susp Inj Syringe High dose frequency lanreotide 120 mg Q2W by deep s.c. injection |
Primary Outcome Measures :
- Phase 1b: RP3D [ Time Frame: 56 days of study treatment ]Incidence of DLTs during the first 56 days of study treatment will be assessed.
- Phase 3: PFS as determined by BICR [ Time Frame: After the target number of 143 PFS events have occurred ]PFS will be defined as the time from the date of randomization until the date of progression (as determined by BICR from tumor assessments using RECIST v1.1) or death due to any cause, whichever occurs earlier.
Secondary Outcome Measures :
- Phase 1b: Cmax [ Time Frame: Up to Day 8 ]
- Phase 1b: Tmax [ Time Frame: Up to Day 8 ]
- Phase 1b: AUC [ Time Frame: Up to Day 8 ]
- Phase 1b: Volume of Distribution [ Time Frame: Up to Day 8 ]
- Phase 1b: Clearance [ Time Frame: Up to Day 8 ]
- Phase 1b: Terminal Half-life [ Time Frame: Up to Day 8 ]
- Phase 1b: TIAC of RYZ101 to critical organs and tumors [ Time Frame: Up to Day 184 ]Calculated mean TIAC (hours) and absorbed radiation dose coefficients (mGy/MBq) to critical organs (e.g., the kidneys and bone marrow) and tumors after the 1st and 4th RYZ101 infusions will be assessed
- Phase 1b: Absorbed radiation doses of RYZ101 to critical organs and tumors [ Time Frame: Up to Day 184 ]Calculated mean TIAC (hours) and absorbed radiation dose coefficients (mGy/MBq) to critical organs (e.g., the kidneys and bone marrow) and tumors after the 1st and 4th RYZ101 infusions will be assessed
- Phase 3: OS [ Time Frame: Up to 80 months or until a total of 130 deaths have occurred, whichever occurs first ]OS will be defined as the time from the date of randomization until the date of death due to any cause.
- Phase 3: ORR by BICR [ Time Frame: Up to 80 months ]ORR, as determined by BICR according to RECIST v1.1.
- Phase 3: PFS [ Time Frame: Up to 80 months ]PFS as determined by Investigator
- Phase 3: ORR by Inv [ Time Frame: Up to 80 months ]ORR, as assessed by the Investigator according to RECIST v1.1
- Phase 3: BOR [ Time Frame: Up to 80 months ]Assessed by BICR and by the Investigator according to RECIST v1.1
- Phase 3: Disease Control Rate [ Time Frame: Up to 80 months ]Assessed by BICR and by the Investigator according to RECIST v1.1
- Phase 3: DoR [ Time Frame: Up to 80 months ]Only for subjects with a RECIST v.1.1 response, assessed by BICR and by the Investigator according to RECIST v1.1
Other Outcome Measures:
- Phase 1b and 3: Incidence and severity of AEs by NCI CTCAE v5, including SAEs, laboratory changes, ECG changes, and other safety findings [ Time Frame: Up to 80 months ]Incidence and severity of AEs by NCI CTCAE v5, including SAEs, laboratory changes, ECG changes, and other safety findings
- Phase 3: Cmax [ Time Frame: Up to 80 months ]
- Phase 3: AUC [ Time Frame: Up to 80 months ]
- Phase 3: Average Concentration [ Time Frame: Up to 80 months ]
- Phase 3: Relationship between exposure endpoints and clinical outcomes [ Time Frame: Up to 80 months ]
- Phase 3: Relationship between biomarkers including but not limited to CgA in the serum and (5-HIAA) in the urine, with AEs of special interest and/or efficacy endpoints (e.g., PFS, OS, BOR, DoR) [ Time Frame: Up to 80 months ]Relationship between biomarkers, including but not limited to CgA in the serum and (5-HIAA) in the urine, with AEs of special interest and/or efficacy endpoints (e.g., PFS, OS, BOR, DoR)
- Phase 3: Changes in EQ-5D-5L questionnaire scores [ Time Frame: Up to 80 months ]
- Phase 3: Changes in EORTC QLQ-C30 questionnaire scores [ Time Frame: Up to 80 months ]
- Phase 3: Changes in EORTC QLQ GI NET21 questionnaire scores [ Time Frame: Up to 80 months ]
- Phase 3: QTc [ Time Frame: Up to 80 months ]Measured by continuous ECG recording using a 12-lead Holter monitoring device
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Subjects must meet all the following criteria for enrollment in the study:
- Histologically proven, Grade 1-2 well differentiated, inoperable, advanced GEP-NETs (Ki67 ≤20%)
- Eastern Cooperative Oncology Group (ECOG) status 0-2
- Life expectancy of at least 12 weeks
-
Subjects with functional tumors who are receiving SSAs on a stable dose for symptom control .
Subjects that do not require octreotide LAR or lanreotide for symptom control must discontinue SSAs at least 4 weeks prior to randomization.
- Progressive, SSTR-PET positive (i.e., Krenning score 3 or 4) GEP-NET (GI or pancreas) based on RECIST v1.1 following 2-4 cycles of treatment with 177Lu-labeled SSA. Must have achieved disease control for at least 6 months following Lu-177 SSA. Radiographic progression must be demonstrated within 18 months of randomization. No time limit is defined between 177Lu-SSA treatment and randomization. Premature discontinuation of Lu-177 SSA treatment should not have been due to PD.
-
Part 2: Subject is a candidate for therapy with 1 of the following SoC options:
- Everolimus 10 mg daily
- Sunitinib 37.5 mg daily
- High-dose octreotide LAR 60 mg Q4W
- High dose frequency lanreotide 120 mg every 2 weeks (Q2W)
- Adequate renal function, as evidenced by creatinine clearance (CrCl) ≥60 mL/min (calculated using the Cockcroft-Gault formula) (Cockcroft and Gault, 1976)
-
Adequate hematologic function, defined by the following laboratory results:
- Part 1: Hemoglobin concentration ≥5.6 mmol/L (≥9.0 g/dL); absolute neutrophil count (ANC) ≥1500 cells/µL (≥1500 cells/mm3); platelets ≥100 x 109/L (100 x 103/mm3)
- Part 2: Hemoglobin concentration ≥5.0 mmol/L (≥8.0 g/dL); ANC ≥1000 cells/µL (≥1000 cells/mm3); platelets ≥75 x 109/L (75 x 103/mm3).
- Total bilirubin ≤3 x upper limit normal (ULN)
- Serum albumin ≥3.0 g/dL unless prothrombin time is within the normal range
- Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 48 hours prior to the first dose of study drug and agree to use barrier contraception and a second form of highly effective contraception (Clinical Trials Facilitation Group [CTFG] 2014) or total abstinence while receiving study drug and for 6 months following their last dose of RYZ101.
- Sexually active male subjects must use a condom during intercourse while receiving study drug and for 3 months after the last dose of the study drug and should not father a child during this period. If sexual partners are WOCBP must also agree to use a second form of highly effective contraception (CTFG 2014) or total abstinence while receiving study drug and for 3 months following their last dose of RYZ101.
- Able to read and/or understand the details of the study and provide written informed consent prior to any study-specific assessments and procedures commence
Subjects who meet any of the following criteria will be excluded from the study:
- Known hypersensitivity to 225Actinium, 68Gallium, 64Copper, octreotate, or any of the excipients of DOTATATE imaging agents
- Part 1: Prior treatment with alkylating agents
- Prior radioembolization
- Any surgery, chemoembolization, and radiofrequency ablation within 12 weeks prior to first dose of study drug
-
Use of anticancer agents within the following intervals prior to the first dose of study drug:
- PRRT: within <6 months
- Chemotherapy: within <6 weeks
- Small molecule inhibitors: within <4 weeks
- Biological agents: within 4 weeks
-
Prior external-beam radiation (EBRT) therapy as defined below:
- Part 1: Any prior EBRT, including SBRT
- Part 2: Prior EBRT within 6 weeks prior to study enrollment or any prior EBRT to more than 25% of the bone marrow
- Prior participation in any interventional clinical study within 30 days prior to first dose of study drug
- Current somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study
- Significant cardiovascular disease, such as New York Heart Association (NYHA) Class ≥II heart failure, left ventricular ejection fraction (LVEF) <40% or QT interval corrected for heart rate using Fridericia's formula (QTcF) >450 ms for males and >470 ms for females.
- Resistant hypertension, defined as uncontrolled blood pressure (BP) >140/90 mmHg while on optimal doses of at least 3 antihypertensive medications with 1 being a diuretic (Whelton et al. 2018)
- Uncontrolled diabetes mellitus as defined by hemoglobin A1C (HgB A1C) ≥8%
- Have a history of primary malignancy within the past 3 years other than (1) GEP-NET, (2) adequately treated carcinoma in situ or non-melanoma carcinoma of the skin, (3) any other curatively treated malignancy that is not expected to require treatment for recurrence during participation in the study, or (4) an untreated cancer on active surveillance that may not affect the subject's survival status for ≥3 years based on clinician assessment/statement and with Medical Monitor approval.
- Known brain, meningeal or spinal cord metastases. In Part 2, subjects with previously treated brain metastases will be allowed if the following conditions are met: (a) there is no evidence of central nervous system (CNS) progression for at least 6 months as assessed by local MRI for brain metastasis during screening; (b) the subject has recovered from acute side effects of radiotherapy; and (c) the subject is receiving a stable or decreasing dose of steroids.
- Subject requires other treatment that in the opinion of the investigator would be more appropriate than the therapy offered in the study
- Pregnancy or lactation
- Unable or unwilling to comply with the requirements of the study protocol
- PRRT other than Lu-177 SSA
- Any condition requiring systemic treatment with high-dose glucocorticoids within 14 days prior to first dose of study treatment and/or which cannot be stopped while on study. Inhaled or topical steroids are permitted.
- Prior history of liver cirrhosis
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05477576
Locations
Show 58 study locations
Sponsors and Collaborators
RayzeBio, Inc.
Investigators
| Study Director: | Denis Ferreira, MD | RayzeBio Sr. Medical Director |
| Responsible Party: | RayzeBio, Inc. |
| ClinicalTrials.gov Identifier: | NCT05477576 |
| Other Study ID Numbers: |
RYZ101-301 |
| First Posted: | July 28, 2022 Key Record Dates |
| Last Update Posted: | April 29, 2024 |
| Last Verified: | April 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by RayzeBio, Inc.:
|
Neuroendocrine Tumors SSTR+ GEP-NET targeted radiotherapy Gastroenteropancreatic Neuroendocrine Tumor RayzeBio Actinium Ac 225 |
Dotatate Everolimus sunitinib octreotide lanreotide PRRT alpha emitter |
Additional relevant MeSH terms:
|
Neoplasms Neuroendocrine Tumors Carcinoid Tumor Intestinal Neoplasms Pancreatic Neoplasms Stomach Neoplasms Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms, Nerve Tissue Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Gastrointestinal Neoplasms Digestive System Neoplasms |
Neoplasms by Site Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases Endocrine Gland Neoplasms Pancreatic Diseases Endocrine System Diseases Stomach Diseases Everolimus Sunitinib Octreotide Lanreotide MTOR Inhibitors Protein Kinase Inhibitors Enzyme Inhibitors |